H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Liquidia Technologies today and set a price target of $35.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andrew Fein’s rating is based on several promising developments within Liquidia Technologies. Firstly, the company is experiencing strong sales momentum with its product Yutrepia, supported by favorable prescription trends and payer dynamics, which suggests a successful first quarter. Additionally, Liquidia is on track to achieve cash-flow positivity and profitability sooner than expected, thanks to disciplined cost management and operational efficiencies.
Moreover, the upcoming R&D Day is anticipated to highlight the L606 program, showcasing new data that could enhance the company’s value and demonstrate its clinical development capabilities. Lastly, despite ongoing patent litigation with United Therapeutics, management remains optimistic about a favorable resolution, which could further benefit Liquidia. These factors collectively contribute to a positive outlook for the company’s growth and profitability, justifying the Buy rating.
Fein covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, United Therapeutics, and KalVista Pharmaceuticals. According to TipRanks, Fein has an average return of 23.0% and a 53.88% success rate on recommended stocks.
In another report released on September 29, LifeSci Capital also maintained a Buy rating on the stock with a $54.00 price target.